VERTEX PHARMACEUTICALS INC / MA Business Combination, Contingent Consideration, Liability
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Business Combination, Contingent Consideration, Liability of $79.60 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities
us-gaap:BusinessCombinationContingentConsiderationLiability · last filed 2026-08-04
- 2026-06-30: Business Combination, Contingent Consideration, Liability $79.60M.
- 2026-03-31: Business Combination, Contingent Consideration, Liability $79.20M.
- 2025-12-31: Business Combination, Contingent Consideration, Liability $79.00M.
- 2025-09-30: Business Combination, Contingent Consideration, Liability $78.10M.
| Period end | Business Combination, Contingent Consideration, Liability |
|---|---|
| 2026-06-30 | $79.60M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $79.20M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $79.00M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $78.10M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $80.00M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $79.10M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $76.90M 10-K · filed 2026-02-13 |
| 2024-09-30 | $78.10M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $77.80M 10-Q · filed 2024-08-02 |
| 2024-03-31 | $77.30M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $77.40M 10-K · filed 2025-02-13 |
| 2023-09-30 | $127.70M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $126.50M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $127.10M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $129.00M 10-K · filed 2024-02-15 |
| 2022-09-30 | $127.20M 10-Q · filed 2022-10-28 |
| 2022-06-30 | $129.80M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $179.00M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $186.50M 10-K · filed 2023-02-10 |
| 2021-09-30 | $188.50M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $187.30M 10-Q · filed 2021-07-30 |
| 2021-03-31 | $185.70M 10-Q · filed 2021-04-30 |
| 2020-12-31 | $189.60M 10-K · filed 2022-02-09 |
| 2020-09-30 | $189.10M 10-Q · filed 2020-10-30 |
| 2020-06-30 | $187.30M 10-Q · filed 2020-07-31 |
| 2020-03-31 | $178.10M 10-Q · filed 2020-05-01 |
| 2019-12-31 | $176.50M 10-K · filed 2021-02-11 |
| 2019-09-30 | $175.00M 10-Q · filed 2019-10-31 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |